NASDAQ: GANX - Gain Therapeutics, Inc.

Yield per half year: -35.02%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Gain Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease.

more details
In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-03-18
ISIN US36269B1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.gaintherapeutics.com
Цена ао 2.09
Change price per day: -3.74% (1.87)
Change price per week: +9.09% (1.65)
Change price per month: -25% (2.4)
Change price per 3 month: -15.89% (2.14)
Change price per half year: -35.02% (2.77)
Change price per year: -43.4% (3.18)
Change price per 3 year: -53.61% (3.88)
Change price per year to date: +15.38% (1.56)
All parameters

Underestimation

Title Value Grade
P/S 631.94 1
P/BV 2.77 6
P/E 0 0
EV/EBITDA -1.09 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -119.66 0
ROE, % -177.03 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0359 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 34.59 5
Yield Ebitda, % 1008.48 10
Yield EPS, % 357.22 10
Total: 9
More

Institutions Volume Share, %
Greenlight Capital, Inc. 588410 3.63
Royal Bank of Canada 200248 1.23
Geode Capital Management, LLC 151476 0.93
CM Management, LLC 90000 0.55
Vanguard Group Inc 88385 0.54
Citadel Advisors Llc 65394 0.4
Prelude Capital Management LLC 58100 0.36
Bridgeway Capital Management, Inc. 46100 0.28
Northern Trust Corporation 43513 0.27
Renaissance Technologies, LLC 42800 0.26



Head Job title Payment Year of birth
Dr. Khalid Islam Ph.D. Executive Chairman 75k 1955 (70 years)
Dr. Joanne Taylor Ph.D. Senior Vice President of Research N/A
Dr. Terenzio Ignoni Pharm.D. Senior Vice President of Technical Operations N/A
Mr. Gene Mack M.B.A. CFO & Interim CEO N/A
Dr. Jonas Hannestad M.D., Ph.D. Chief Medical Officer N/A

Address: United States, Bethesda. MD, 4800 Montgomery Lane - open in Google maps, open in Yandex maps
Website: https://www.gaintherapeutics.com